We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Mexico IVD Market Valued at USD 405 Million for 2016

By LabMedica International staff writers
Posted on 07 Aug 2017
Mexico's in vitro diagnostic (IVD) market is valued at USD 405 million for 2016, making it the second largest in Latin America, and is considered moderate in its regulatory process and foreign investment opportunities. More...
These are the latest findings of Kalorama Information, (New York, NY, USA), an independent medical market research firm.

Mexico is the world’s twelfth most populated country with 123.2 million people residing in the country in 2016 and is the second-largest country in Latin America in terms of population, accounting for 20% of the region's total. The World Health Organization (WHO) estimates Mexico's healthy life expectancy at birth at 68 years, which is 9 years less than the total life expectancy for the country at birth. In spite of the increase in life expectancy and slight increase in healthy life expectancy, the Mexican population is likely to witness increasing chronic disease, disability and morbidity due to lifestyle trends resulting in obesity and diabetes. Thus, Mexico’s IVD market is being supported by its growing population and its more rapidly increasing aging population.

Mexico's health sector is a mix of both private and public structures with the private sector responsible for a majority of the laboratory business in the country. Mexico is exhibiting an upward trend in per capita spending on IVD, with large private hospitals in the country increasing their capital equipment budgets to accommodate more advanced testing technologies. The Mexican business environment for medical devices and equipment is favorable and relatively streamlined for U.S. and European participants. There is a growing demand for new technologies in the laboratory sector and, as government and private hospital budgets increase, the market is expected to witness an increase in demand for high-tech equipment and consumables.

Related Links:
Kalorama Information


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TRAcP 5b Assay
TRAcP 5b (BoneTRAP) Assay
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.